NCT07622667 Correlation Analysis of Gene Characteristics of Malignant Tumors With Prognosis
| NCT ID | NCT07622667 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Nanfang Hospital, Southern Medical University |
| Condition | Malignant Tumors |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2026-05-29 |
| Primary Completion | 2027-01-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2026-05-29 with a primary completion date of 2027-01-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is a single-center observational investigation aimed at systematically exploring the key molecular features influencing the prognosis of malignant tumors by integrating multidimensional clinical information with multi-omics molecular data. The goal is to provide a critical scientific basis for constructing precise prognostic prediction models, identifying potential therapeutic targets, and optimizing clinical treatment strategies. The study plans to consecutively enroll adult patients with histologically confirmed malignant tumors who received antitumor therapy at our hospital between January 2017 and December 2025. Clinical data (including demographic characteristics, tumor pathology information, treatment histories, and survival follow-up data) will be systematically collected from electronic medical records. Additionally, tumor tissue or blood samples will be obtained from the patients for sequencing, staining, ELISA, drug sensitivity testing, and flow cytometry analysis to comprehensively characterize the genomic features, immune microenvironment, and cellular heterogeneity of the tumors.
Eligibility Criteria
Inclusion Criteria: 1. Voluntarily sign the informed consent form. 2. Treated at Nanfang Hospital, Southern Medical University between January 2017 and December 2025. 3. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2. 4. Availability of surplus routinely discarded clinical tumor tissue samples (biopsy specimens or pathological sections) or blood samples for assays such as sequencing, staining, ELISA, drug sensitivity testing, and flow cytometry. Exclusion Criteria:Patients deemed by the investigator to be unsuitable for participation in this study.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07622667 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Malignant Tumors. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07622667 currently recruiting?
Yes, NCT07622667 is actively recruiting participants. Contact the research team at 29262574@qq.com for enrollment information.
Where is the NCT07622667 trial being conducted?
This trial is being conducted at Guangzhou, China.
Who is sponsoring the NCT07622667 clinical trial?
NCT07622667 is sponsored by Nanfang Hospital, Southern Medical University. The trial plans to enroll 500 participants.